KRAS Mutation Screening (Codons 12 & 13) in UAE | 1400 AED | DHA Approved

Executive Summary & Core Metrics

Clinical Excellence & Operational Integrity

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Secure Medical Courier Retrieval of Archival Tissue Specimen – formalin-fixed paraffin-embedded blocks or slides. Home phlebotomy is not applicable for this test.
Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed specialists.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 (Provide policy details for immediate confirmation).

Test Overview & Methodology

KRAS Mutation Screening (Codons 12 & 13) detects somatic mutations in the KRAS oncogene, critical for guiding anti-EGFR therapy in metastatic colorectal cancer and influencing prognosis in pancreatic, lung, and gynecologic malignancies. This test uses Sanger Sequencing on formalin-fixed paraffin-embedded tumor tissue, delivering results within 7–8 days at 1400 AED, and is requested by oncologists, gynecologists, and medical geneticists to tailor targeted treatment.

Feature	Our Test (DHA Approved)	Closest Alternative
Method	Sanger Sequencing (Gold Standard for KRAS codons 12/13)	Pyrosequencing or Real-time PCR
Sensitivity	99.9% Diagnostic Sensitivity	~95% (varies by platform)
Turnaround Time	7–8 Days	10–14 Days
Regulatory Compliance	Full DHA, PDPL & Federal Law No. 2 of 2019	Varies

Physician Insight & Safety Protocols

Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA Registration ID: 61713011) notes: “KRAS mutation testing is a cornerstone of personalized oncology; however, a negative result does not exclude the possibility of other mutations or resistance mechanisms. Clinical correlation with imaging, pathology, and other biomarkers is essential. Continue all prescribed medications and follow your oncologist’s advice without interruption, as this test is for treatment stratification, not standalone diagnosis.”

Advisory Notes

Medication & Dietary Guidance

Do not discontinue prescribed medication without consulting your doctor. No special dietary restrictions are required for tissue biopsy procurement.

Exclusion Criteria

Safety & Contraindications

Prescription Mandatory: A valid physician's prescription is required. Exceptions: Not applicable for surgery clearance, pregnancy routines, or travel abroad purposes.
Pediatric Restriction: Testing on minors (under 18) strictly requires documented guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Sample Adequacy: Tumor tissue must contain at least 20% neoplastic cells; insufficient specimens may not yield reliable results.
Emergency Red Flags: If you experience acute bleeding, severe pain at the biopsy site, or signs of infection, seek immediate emergency care. This test does not replace urgent clinical evaluation.

Patient FAQ & Clinical Guidance

1. What does a KRAS mutation test result mean for my cancer treatment?

The presence of a KRAS codon 12 or 13 mutation indicates resistance to anti-EGFR monoclonal antibodies (cetuximab, panitumumab) in metastatic colorectal cancer, guiding oncologists to alternative therapies. Your result, combined with other markers, tailors your personalized treatment plan.

2. How long does it take to receive KRAS mutation test results?

The report is issued within 7 to 8 business days from receipt of a qualified archival tissue specimen. Telephonic post-test consultation with a DHA-licensed specialist is available for prompt interpretation.

3. Do I need to fast or stop medications before a KRAS tissue test?

No fasting or medication adjustments are necessary since the test is performed on previously obtained tumor tissue (biopsy or surgical specimen). Always consult your oncologist before making any changes to your treatment regimen.

UAE Regulatory & Data Privacy Adherence

Your data is protected under: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical and genetic information is handled with strict confidentiality and processed in DHA-licensed facilities adhering to ISO 9001:2015 standards. Your consent is obtained per Federal Decree-Law No. 4 of 2016 on Medical Liability for any specimen procurement.

Clinical & Logistical Metadata

Test Name	KRAS Mutation Screening (Codons 12 & 13)
Price (AED)	1400 AED
Turnaround Time	7–8 Business Days from receipt of specimen
Sample Type / Matrix	Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue (Archival Specimen) – Secure Medical Courier Retrieval
Methodology Used	Sanger Sequencing
ICD-10-CM Code	C18.9
LOINC Code	21572-2
DHA Facility License & Address	License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| Corporate Lab: DNA Labs UAE